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Angiogenesis and metabolism are entwined processes that permit tumor growth and 23 
progression. Blood vessel supply is necessary for tumor survival by providing oxygen and 24 
nutrients for anabolism, but also by removing waste products from cellular metabolism. On 25 
the other hand, blocking angiogenesis with antiangiogenic therapies shows clinical benefits 26 
in several tumor types. Nevertheless, resistance to therapy emerges over time. In this 27 
review, we will discuss a novel mechanism of adaptive resistance involving metabolic 28 
adaptation of tumor cells, as well as provide examples of tumor adaptation to therapy, 29 
which may represent a new mechanism of resistance in several types of cancer. Thus, 30 
targeting this metabolic tumor adaptation could be a way to avoid resistance in cancer 31 
patients. 32 
 33 
Angiogenesis and Metabolism as Therapeutic Target  34 
In 1971, Judah Folkman proposed that tumor growth is dependent on angiogenesis and its 35 
inhibition could be used for cancer treatment. Since then, several antiangiogenic drugs have 36 
been developed and are currently in clinical use[1]. More recently, the “Hallmarks of 37 
Cancer” highlighted the role of angiogenesis and metabolism in tumor progression [2]. And 38 
in the update published in 2011 ("Hallmarks of cancer: the next generation"), Weinberg and 39 
Hanahan proposed the deregulation of cellular energy as a new hallmark[3]. Thus, 40 
angiogenesis and metabolism are key for tumor progression. But more importantly, they are 41 
highly entwined processes that share common molecules and signaling 42 
pathways[4].Therefore, these common molecular hubs are not only logical targets for 43 
therapy but also are critical regulators of tumor adaptation to anti-vascular or anti-44 
metabolic therapies. During the last years, the important role that hypoxia and metabolism 45 
play in tumor adaptation to antiangiogenic treatment has been described. Metabolic 46 
reprogramming in tumors contributes to their growth either by directly supporting cancer 47 
cell proliferation or by shaping the microenvironment potentially favoring tumor cell 48 
survival.  Pre-clinical studies combining antiangiogenic therapies with anti-metabolic 49 
therapies have shown great promise, and clinical trials are being performed. Here, we 50 
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review the link between these two important processes with a particular focus on new 51 
therapeutic opportunities to prevent tumor metabolic adaptation. 52 
 53 
Angiogenesis, Hypoxia, and Metabolism in Tumor Tissues 54 
Angiogenesis is stimulated when tumor tissues require nutrients and oxygen and is 55 
necessary for tumor growth and progression[5]. The growth of new blood vessels is 56 
regulated by a balance of pro- and antiangiogenic signals, including the increase in secretion 57 
of various proangiogenic growth factors such as vascular endothelial growth factor (VEGF), 58 
fibroblast growth factors (FGFs), angiopoietins (Ang), placental growth factor (PlGF) and 59 
some integrins, and concomitantly decrease of several anti-angiogenic factors, such as: 60 
angiostatin, endostatin, interferons, platelet factor 4, thrombospondin, and tissue inhibitor 61 
of metalloproteinase-1, -2, and -3 [6]. When this balance is lost, an abnormal vascular 62 
network that is characterized by dilated, tortuous, and hyperpermeable vessels is created 63 
[7]. Therefore, tumor vasculature is typically chaotic with dead-end vascular branches and 64 
areas of inverted and intermittent blow flow. Some of these areas have impaired vascular 65 
function and lead to regions of lowered perfusion and hypoxia[8]. Indeed, hypoxia promotes 66 
vessel growth by up regulating multiple pro-angiogenic pathways that mediate key aspects 67 
of endothelial, stromal, and vascular support cell functions[9]. 68 
Clinically, tumor hypoxia is associated with poor patient prognosis and resistance to 69 
chemotherapy[10]. Hypoxia regulates the expression of many genes under the 70 
transcriptional control of hypoxia-inducible factors (HIF1α and HIF2α), which heterodimerize 71 
with HIF1β and bind to the hypoxia response element (HRE) [11].HIF1α and HIF2α 72 
phosphorylation and activation can be modulated by growth factors’ signaling cascades such 73 
as PI3K/AKT/mTOR and MAPK [12].Many of the genes regulated by HIF lead to more 74 
aggressive growth and survival of tumor cells that contribute to cancer development and 75 
progression, as HIF is a key regulator of tumor growth, particularly of angiogenesis and 76 
metabolism. 77 
The metabolic characteristics of normal and tumor cells are different. Tumor metabolic 78 
needs are higher based on cancer phenotypic changes including increased proliferation and 79 
survival in a tumor microenvironment with low levels of oxygen, nutrients, and acidic 80 
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extracellular pH[13]. Indeed, cancer cells have an altered metabolism that induces 81 
metabolic reprogramming producing the activation of target genes by HIF, which decreases 82 
cellular dependency on oxygen. Oncogenic transformation itself with genes such as RAS, 83 
MYC, and AKT can also upregulate glucose consumption, glycolysis and the loss of 84 
phosphorylation of TP53 (best known as p53). This transformation may also recapitulate the 85 
features of the Warburg effect, that is, the uncoupling of glycolysis from oxygen levels 86 
[14].Thus, tumor metabolism is highly related with tumor initiation and progression, and 87 
may also play a role in tumor response to anti-cancer treatments. 88 
On the other hand, hypoxia and HIF signaling regulate many metabolic processes and 89 
metabolic intermediates. One of these processes is the increment of glutamine uptake. 90 
Glutamine is used in the tricarboxylic acid (TCA) cycle as an alternative to pyruvate, and also 91 
reduces oxidative phosphorylation by preventing pyruvate from entering the TCA [15, 92 
16].The pentose phosphate pathway (PPP) is up-regulated in cancer, and stabilization of 93 
HIF1α increases expression of genes involved in the PPP [17]. Furthermore, previous studies 94 
indicated a link between glutamine metabolism and mTOR signaling, which led investigators 95 
to consider the possible involvement of glutamine and the metabolism of lactate in the 96 
induction of mTOR signaling [18, 19]. Overall, it is well established that there is a 97 
bidirectional relationship between HIF/hypoxia and metabolism, both at the 98 
glycolysis/lactate and TCA/glutamine levels. 99 
Tumor hypoxia also triggers the production of metabolic acids, such as lactic acid, as 100 
products of anaerobic glycolysis [20]. Therefore, fine regulation of pH is a critical aspect for 101 
maintaining the optimum conditions of cell functions[21]. Thus, under hypoxia many pH 102 
regulatory proteins are upregulated or show increased activity, e.g. monocarboxylate 103 
transporters 1 and 4 (MCT1 and MCT4) that export lactate, which are important for pH 104 
regulation in the tumor extracellular microenvironment [20].The resulting acidosis from 105 
upregulated glycolysis is considered to be a key factor in the invasiveness and metastatic 106 
activity of cancer cells as they try to escape the toxic microenvironment [22] 107 
Furthermore, cancer cells may also have altered metabolic interactions within 108 
subpopulations of cancer cells or with the microenvironment, both of which may alter 109 
overall tumor metabolite levels [23]. Moverover, metabolic requirements of in tumors are 110 
define by tissue of origin, epigenetic drivers, aberrant signaling and tumor 111 
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microenvironment [24]. Furthermore, is important to mention that endothelial cells’ 112 
metabolism can also considered as a possible novel therapeutic target [25]. Concomitantly 113 
understanding the dynamics of endothelial and cancer cell metabolism will provide new 114 
avenues for clinical strategies. On the other hand, it has been described that for each cancer 115 
types, its different metabolism supports the oncogenic phenotype. It is therefore important 116 
to evaluate the therapeutic potential of metabolism targeting, based on the concepts of 117 
metabolic normalization and metabolic depletion (See Box 1). 118 
Overall, angiogenesis and metabolism are entwined in tumor growth: Hypoxia leads to 119 
angiogenic growth factors production that initiates angiogenesis; angiogenesis provides 120 
oxygen to the tumor; this angiogenesis also provides nutrients for cell metabolism, which 121 
produces energy for angiogenesis and cell proliferation. As oxygen is scarce, tumor 122 
metabolism is predominantly glycolysis which acidifies the environment; this acidity can 123 
impede metabolic enzymes. Cancer cells can also avoid apoptosis by ignoring apoptotic 124 
signals, which can ultimately alter the outcome of anti-cancer therapies. Indeed, hypoxia 125 
decreases the efficacy of chemotherapy and radiotherapy. 126 
Therefore, these entwined tumor processes could be exploited therapeutically: 127 
angiogenesis is targeted by antiangiogenic agents, metabolic inhibitors could halt ATP 128 
production, buffer therapies could normalize acidity, and molecular inhibitors could 129 
overcome therapy resistance. 130 
 131 
Tumor Responses to Antiangiogenic Therapy 132 
Many antiangiogenic drugs are clinically used in several types of cancer to block 133 
angiogenesis, impair tumor growth, progression and dissemination[26]. Most antiangiogenic 134 
therapies target VEGF and its receptors (VEGFRs) [27]. The initial hypothesis was that 135 
antiangiogenesis therapy would not induce resistance (“resistant to resistance”) because it 136 
targeted the genetically more stable endothelial cells instead of the more unstable tumor 137 
cells [28]. 138 
Nevertheless, as in most systemic therapies, resistance to antiangiogenic treatments occurs, 139 
involving both upfront refractoriness (intrinsic resistance), and acquired resistance that is 140 
gained over the duration of the treatment. Intrinsic resistance is characterized by tumor 141 
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indifference to antiangiogenic therapy, and in patients receiving antiangiogenics such as 142 
bevacizumab, sorafenib or sunitinib, tumors continue to grow in spite of treatment [29]. On 143 
the other hand, acquired resistance to antiangiogenics seems to stem from tumor 144 
adaptations to therapy instead of mutations or gene amplifications that typically 145 
characterize acquired resistance to other therapeutic strategies. In this form of resistance, 146 
alternative mechanisms are created that lead to activation of additional proangiogenic 147 
signaling even when the target of the drug remains inhibited [30-33]. In fact, clinical 148 
evidence of this plasticity has been described in metastatic renal cell carcinoma (RCC) 149 
treated repeatedly with VEGFR inhibitors[34]. Indeed, several clinical trials report an upfront 150 
failure of these therapies in some patients, and also a lack of long-lasting effects of 151 
antiangiogenic agents as consequence of tumor adaptation to the therapy. 152 
 153 
Antiangiogenic Resistance via Metabolic Symbiosis 154 
Recently, a new mechanism of resistance to antiangiogenic therapies was described that 155 
involves an induction of metabolic symbiosis between subpopulations of tumor cells [35-156 
37]. Surprisingly, in this case, emergence of resistance is not associated with tumor 157 
revascularization but rather with metabolic changes occurring in tumor cells (Figure 1, Key 158 
Figure). 159 
Some years ago, Sonveaux et al described a coordinated mechanism in the metabolism of 160 
cancer cells allowing the establishment of metabolic symbiosis: tumor cells in hypoxic areas 161 
up-regulate glycolysis, increase lactate production, and export lactate through MCT4. On the 162 
other hand, this excess of lactate is taken up by tumor cells in more oxygenated areas of the 163 
tumor via SLC16A1 (best known as MCT1), and aerobically metabolize it via the 164 
mitochondria [38].  165 
Recently, three independent laboratories have reported that this mechanism is used by 166 
tumors to evade antiangiogenic treatment [35-37]. 167 
Allen et al. observed in pancreatic neuroendocrine tumor (PanNET) mouse models that 168 
antiangiogenic inhibitors, sunitinib and axitinib, elicit compartmentalization of cancer cells 169 
into symbiotic clusters, which are the spatial relationship between the cell populations in 170 
the metabolic symbiosis: when glucose and oxygen concentrations are high (near blood 171 
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vessels), the cells preferentially utilize glucose-fuelled respiration; but when the oxygen 172 
supply is depleted (far from vessels), the cells rely on anaerobic glycolysis. The glycolytic 173 
cells produce large quantities of lactate which are consumed by cells close to vessels. In the 174 
study, the authors also present data to support a mechanism whereby cancer cells take up 175 
and metabolize lactate in the context of bioavailable glutamine in normoxic, but not hypoxic 176 
conditions, thereby up regulating mTOR signaling. Moreover, they described that co-177 
inhibition of mTOR with rapamycin disrupts the symbiosis by up regulating glucose transport 178 
in normoxic cells[35]. 179 
On the other hand, Pisarsky et al. described in preclinical mouse model of breast cancer the 180 
role of metabolic symbiosis as a mechanism underlying evasive resistance to antiangiogenic 181 
therapy with the multikinase inhibitors nintedanib and sunitinib. Inhibition of glycolysis or 182 
genetic ablation of SLC16A4caused disruption of metabolic symbiosis, suppression of tumor 183 
growth and prevented the emergence of resistance [37]. In yet another study, we described 184 
the induction of MCT1/MCT4 lactate transporters in a pattern of metabolic symbiosis in RCC 185 
patient-derived orthoxenograft mouse models treated with sunitinib. This symbiosis was 186 
blocked using mTOR inhibitors, affecting cells close to vessels and eliminating the hypoxic 187 
regions and impairing tumor growth [36]. The concept of metabolic symbiosis is not new; 188 
some years ago it was described by Dewhirst, Sonveaux, Feron and colleagues [38]. 189 
However, there is clear evidence that this concept can now be extended to the metabolic 190 
symbiosis that occurs in response to treatment with antiangiogenic drugs as a new 191 
mechanism of resistance to the therapy. This is caused by stress in the tumor 192 
microenvironment due to decreased tumor vasculature and exacerbated intratumor 193 
hypoxia.  194 
Thus, here again, the close implications between the process of angiogenesis inhibition and 195 
changes in metabolism is well established, in this case as an adaptive mechanism in 196 
response to treatment. Furthermore, from a therapeutic perspective, blocking this 197 
metabolic adaptation could have a significant value, as we envision the use of anti-198 





Clinical trials  202 
Antiangiogenic drugs used in the clinic extend survival in the order of months in some 203 
cancer settings while failing to induce survival benefit in others, in part because of intrinsic 204 
refractoriness or evasive escape[39]. Very recently, exciting novel concepts involving 205 
blocking angiogenesis and metabolic adaptation have emerged from preclinical research, 206 
which could prevent the emergence of resistance in the clinics. 207 
Clinical trials using mTOR inhibitors as a second line treatment in combination or not with 208 
other therapies including antiangiogenics have been initiated. In particular, there are 17 209 
open clinical trials and 19 clinical studies already completed with or without results, based 210 
on CinicalTrials.gov (Table 1).For years it has been thought that double inhibition of two 211 
important pathways such as VEGF and mTOR was unfavorable in terms of efficacy in 212 
particular due to increased toxicity [40]. Nowadays, this trend is changing because there are 213 
new preclinical and clinical data providing evidence of effectiveness and moderate toxicity 214 
of this combination. In particular, Motzer and colleagues tested a new VEGF receptor 215 
inhibitor, levantinib, alone or in combination with everolimus for a second line therapy in 216 
patients who had progressed to a first line antiangiogenic. They observed promising efficacy 217 
results with the dual combination not only in progression free survival but also in overall 218 
survival [41]. They also observed tolerable side effects in 20%of patients in the combinatory 219 
group. Recently, in the RECORD-4 clinical trial everolimus demonstrated a favorable benefit-220 
risk profile used as a second-line in mRCC (metastatic renal cell carcinoma) patients who 221 
progressed after a first-line anti-VEGF therapy [42]. In addition, final overall survival (OS) 222 
analysis supports everolimus as a second-line option in mRCC patients who were previously 223 
treated with sunitinib, other anti-VEGF therapy, or cytokines. Based on these results, the 224 
efficacy of everolimus as a second-line treatment in mRCC patients has been demonstrated 225 
[42]. Nevertheless, it is necessary to keep adequate patient follow-up and control the dose 226 
to avoid the occurrence of side effects.  227 
 228 
Concluding Remarks  229 
The process of angiogenesis and the metabolic pathways in a tumor cell are intimately 230 
entwined during cancer growth and disease development. Hypoxia is a key element in the 231 
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induction of neovessel formation, but is also critical in the regulation of metabolism. Indeed, 232 
hypoxia response programs  typically include many metabolic genes, but also many 233 
angiogenesis-regulatory molecules [43]. Therefore, it is not surprising to see the close 234 
implication of these processes also in therapeutic resistance. Indeed, a recently described 235 
form of tumor resistance to antiangiogenic therapies involves a metabolic rewiring of the 236 
carbohydrate energy pathways in the form of metabolic symbiosis. But even more 237 
importantly, it also opens new avenues for treatment strategies aimed at inhibiting both  238 
metabolism and angiogenesis. 239 
The current challenge is to overcome the idea that cancer metabolism is a unique and 240 
consistent entity, and analyze tumor metabolism in the context of tissue origin, genetics and 241 
epigenetics change of individual tumors, signaling aberrations, heterogeneity of cancer cells 242 
and the associated tumor microenvironment. Nowadays, tumor metabolism offers a wide 243 
range of targeted drugs that can be exploited for cancer therapy.Therefore, taking into 244 
account tissue variability and the specific metabolism of each tumor could give us the 245 
possibility to select specific drugs and use therapeutic strategies based on metabolism. 246 
Therefore, for the combination of anti-metabolic drugs together with antiangiogenics, a 247 
logical therapeutic strategy could be the use of an antiangiogenic drug as first-line 248 
treatment and, at the moment of resistance, follow on by second-line treatment aimed at 249 
blocking metabolic adaptation. Nevertheless, it is not yet clear whether suppression of VEGF 250 
pathway should be maintained in the second-line treatment in order to sustain the tumor 251 
metabolic adaptation. In this case, addition of anti-metabolic drugs on top of 252 
antiangiogenics (added combination) could demonstrate extended benefits. While these 253 
particular combinations have not been fully tested yet in patients, the current clinical 254 
approaches tend to use combination strategies rather than sequential monotherapies [44]. 255 
Overall, targeting angiogenesis and tumor metabolic reprogramming could be a new 256 
opportunity for cancer treatment (See Outstanding Questions). Furthermore, identifying 257 
new predictors of response or biomarkers of resistance to antiangiogenic therapies would 258 
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Legend to Key Figure 362 
Figure 1: Response to antiangiogenic therapies and resistance by metabolic 363 
symbiosis.  364 
Vascularized angiogenic tumors are treated with antiangiogenic therapy, which elicits 365 
regression of tumor vasculature causing an increase in hypoxia and tumor shrinkage. 366 
Hypoxia modulates different growth factors and signaling cascades, such as the mTOR 367 
pathway, which can trigger tumor adaptation to therapy. Resistance to antiangiogenic 368 
therapies involves tumor plasticity mechanisms, such as the establishment of metabolic 369 
symbiosis between cancer cells. Tumor cells in hypoxic regions (blue) up-regulate glycolysis, 370 
increase lactate production and export lactate through the transporterMCT4. On the other 371 
hand, lactate is taken up by normoxic cancer cells via MCT1 and is aerobically metabolized in 372 
the mitochondria. This symbiotic mechanism is used to evade antiangiogenic therapies and 373 
allows resistance and tumor progression.  374 
  375 
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Glossary  376 
Anaerobic glycolysis: transformation of glucose to lactate when limited amounts of oxygen 377 
(O2) are available. 378 
Angiogenesis:   formation of new blood vessels from pre-existing vessels.  379 
Antiangiogenics:  class of anti-cancer therapies that target the tumor vasculature. 380 
Antiangiogenic resistance: process that involves different mechanisms in the tumor that 381 
allow evasion of therapy. 382 
. 383 
Endothelial cells: form a single cell layer that lines all blood vessels and regulates molecule 384 
exchanges between the bloodstream and the surrounding tissues. 385 
Hallmarks of cancer: constitute an organizing principle for rationalizing the complexities of 386 
neoplastic disease. 387 
Hypoxia: condition where the tissues are not oxygenated adequately, usually due to an 388 
insufficient concentration of oxygen in the blood. 389 
Hypoxia-inducible factor:  key regulator that plays an integral role in the body's response to 390 
low oxygen concentrations 391 
Hypoxic and metabolic adaptation to antiangiogenic therapy: changes that occur in tumor 392 
cells in response to low levels of oxygen and nutrients that allow tumor cells to survive in 393 
these conditions.   394 
Glycolysis:   metabolic pathway that converts glucose into pyruvate. 395 
Metabolic symbiosis: mechanism of resistance where hypoxic cancer cells import glucose 396 
and export lactate, while normoxic cells import and catabolize lactate. 397 
Warburg effect: describes the increased utilization of glycolysis rather than oxidative 398 
phosphorylation by tumor cells for their energy requirements under physiological oxygen 399 
conditions. This effect has been the basis for much speculation on the survival advantage of 400 




· Angiogenesis and metabolism are entwined processes during tumor development 
and their interface offers unprecedented opportunities for therapeutic 
intervention.  
· Antiangiogenic drugs are currently used in the clinic but therapy resistance 
emerges over time with disease progression. Recently, metabolic symbiosis has 
emerged as a new mechanism of resistance to these therapies. 
· Metabolic symbiosis is a tumor compartmentalization where hypoxic regions (far 
from blood vessels) are highly glycolytic and they generate high amounts of 
lactate. In contrast normoxic regions (close to blood vessels) uptake the excess of 
lactate and metabolize it by aerobic mitochondrial respiration. With this 
mutualistic balance tumors evade antiangiogenic therapies and continue to grow.  
· Targeting angiogenesis and metabolic adaptation could substantially extend the 






Outstanding Questions Box 1 
 2 
· How could the Warburg effect influence drug efficacy? 3 
· Can we exploit tumor energetics knowledge to improve drug development? 4 
· Could there be synergy in combining antiangiogenic therapies and metabolic 5 
inhibition? 6 
· Would they interact with standard chemotherapy? What about the scheduling of 7 
these combinations of therapies? 8 
·  Could they be used in different disease stages (metastatic, adjuvant, neoadjuvant)?  9 
· Are there potential predictive biomarkers of response to these combination 10 
therapies? 11 
· Should we develop metabolic drugs into personalized cancer medicines? 12 
· Which are the biological consequences of sustained suppression of angiogenesis on 13 
tumor biology and normal tissue homeostasis? 14 
· Should we combine antiangiogenic drugs with anti-resistance targeting agents at the 15 
time of resistance or earlier? 16 
· Why are surrogate markers or biomarkers of angiogenesis and antiangiogenesis still 17 
so elusive and not yet clinically applied? 18 
